Aspergillus, angiogenesis, and obesity: the story behind beloranib.

Beloranib, a fumagillin analog that is an angiogenesis inhibitor and associated with decreased adiposity in animals, has been studied in phase I clinical trials for cancer and is currently being investigated for the treatment of obesity and related conditions.